{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:13:58Z","timestamp":1761844438298},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.76","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T14:16:12Z","timestamp":1415974572000},"page":"e258-e258","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"4","author":[{"given":"J E","family":"Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Y","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Almahasnah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D F","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"key":"BFbcj201476_CR1","first-page":"1431","volume-title":"Williams Hematology","author":"TJ Kipps","year":"2010","unstructured":"Kipps TJ . Chronic lymphocytic leukemia and related disorders Kaushansky K, Beutler E, Kipps T, Seligsohn U, Prchal J Williams Hematology. New York: McGraw-Hill, 2010. p 1431\u20131482."},{"key":"BFbcj201476_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2011.1.110","volume":"2011","author":"JR Brown","year":"2011","unstructured":"Brown JR . The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 110\u2013118.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbcj201476_CR3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/1042819021000006547","volume":"43","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755\u20131762.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201476_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32\u201342.","journal-title":"N Engl J Med"},{"key":"BFbcj201476_CR5","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286\u20132294.","journal-title":"N Engl J Med"},{"key":"BFbcj201476_CR6","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/cncr.28292","volume":"119","author":"T Shanafelt","year":"2013","unstructured":"Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, Laplant B et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 2013; 119: 3788\u20133796.","journal-title":"Cancer"},{"key":"BFbcj201476_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749\u20131755.","journal-title":"J Clin Oncol"},{"key":"BFbcj201476_CR8","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446\u20135456.","journal-title":"Blood"},{"key":"BFbcj201476_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165\u20132170.","journal-title":"J Clin Oncol"},{"key":"BFbcj201476_CR10","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/leu.2008.214","volume":"22","author":"JE Castro","year":"2008","unstructured":"Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048\u20132053.","journal-title":"Leukemia"},{"key":"BFbcj201476_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/leu.2009.133","volume":"23","author":"JE Castro","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23: 1779\u20131789.","journal-title":"Leukemia"},{"key":"BFbcj201476_CR12","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1200\/JCO.2014.55.8262","volume":"32","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM et al. Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma: Results from the phase III RESONATE trial. J Clin Oncol 2014; 32: 5s.","journal-title":"J Clin Oncol"},{"key":"BFbcj201476_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88\u201394.","journal-title":"J Clin Oncol"},{"key":"BFbcj201476_CR14","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","volume":"119","author":"G Salles","year":"2012","unstructured":"Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119: 5126\u20135132.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201476","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:57:41Z","timestamp":1672959461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,14]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"alternative-id":["BFbcj201476"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.76","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,14]]},"assertion":[{"value":"30 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}